TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00852501

Intervention type: OTHER
Intervention: To perform RT-PCR on the tissue obtained during surgery
Description: The performance of surgery is the standard of care in the management of non-functioning pituitary macroadenomas. The tissue obtained during surgery is routinely sent for histopathological examination. A piece of the tissue will undergo receptor characterisation via RT-PCR.
Study: NCT02925403

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: R21/Matrix-M1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: R21/Matrix-M1

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT03395457

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual
Description: Application of usual pharmacological care for chronic migraine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Care as usual
Description: Application of usual pharmacological care for chronic migraine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: 5 sessions of manual therapy over 12 weeks
Study: NCT03912935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: comparison between two different intubating position
Description: Comparing to different position (sniffing and BUHE) in endotracheal intubation for rapid sequence induction in simulated emergency cases
Study: NCT05296174

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive-oriented intervention program
Description: The experimental group was offered six 40-minute courses once a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: health education activities program
Description: The control group was offered health education activities once a week.
Study: NCT02396511

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRC105
Description: weekly i.v. TRC105 in combination with every 2 weeks i.v.bevacizumab, until progression or unacceptable toxicity develops

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Every 2 weeks i.v.bevacizumab in combination with weekly i.v. TRC105, until progression or unacceptable toxicity develops
Study: NCT05088850

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT00711880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex®
Description: containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
Study: NCT00810511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon A contact lens
Description: Silicone hydrogel contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comfilcon A contact lens
Description: Silicone hydrogel contact lens
Study: NCT04323943

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle Foot orthosis (AFO)
Description: The experimental protocol will require 4 visits: one inclusion visit and 3 visits for evaluations. Each visit corresponds to one condition: C-AFO, CM-AFO or NO (according to a random order).~Visit #1 will consist in a clinical evaluation and a familiarization session with the measuring devices and methodologies used in visit#2 #3 and #4.~During #2, #3 and #4 visits (14 days between each session), the subject will perform with C-AFO, CM-AFO or NO according to the random order :~* 5 x 15m overground at a comfortable walking speed (CWS) where EMG, ground reaction force and kinematics will be measured~* 6MWT where energy cost will be measured~* 5 x 15m overground (immediately after the 6MWT) at a comfortable walking speed

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ankle Foot orthosis (AFO)
Description: The experimental protocol will require 4 visits: one inclusion visit and 3 visits for evaluations. Each visit corresponds to one condition: C-AFO, CM-AFO or NO (according to a random order).~Visit #1 will consist in a clinical evaluation and a familiarization session with the measuring devices and methodologies used in visit#2 #3 and #4.~During #2, #3 and #4 visits (14 days between each session), the subject will perform with C-AFO, CM-AFO or NO according to the random order :~* 5 x 15m overground at a comfortable walking speed (CWS) where EMG, ground reaction force and kinematics will be measured~* 6MWT where energy cost will be measured~* 5 x 15m overground (immediately after the 6MWT) at a comfortable walking speed
Study: NCT02587078

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Volulyte
Description: Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Jonosteril
Description: Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
Study: NCT00734058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser MAZE by Ablation of Cardiac Tissue
Description: The protocol calls for the creation of the pulmonary vein isolation lesion through the use of the SOLAR™. The additional lesions are to be created using the ATRILAZE™. At surgeon discretion, the ganglia may be ablated and left and right atrial appendages may be removed.
Study: NCT03576664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol 25mg
Description: Cross-over, randomized, placebo-controlled study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol 25mg
Description: Cross-over, randomized, placebo-controlled study.
Study: NCT00602732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Reach Out for a Safe Environment (ROSE) program
Description: Participants in the ROSE program will receive a course on managing stress and negative feelings and will learn how to access resources for help. The ROSE program involves four 90-minute group sessions over a 4-week period prior to delivery. Participants will also attend one 50-minute booster session within 4 weeks prior to delivery of their babies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced care as usual (ECU)
Description: Participants in ECU will receive the usual medical care provided for pregnant women at their prenatal clinic. Participants will also receive educational material and a list of treatment resources for depression.
Study: NCT04334876

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SARS-CoV-2 IgG Antibody Testing Kit
Description: A, finger prick, at home test for SARS-CoV-2 IgG Antibodies.
Study: NCT03782389

Intervention type: OTHER
Intervention: Preseason Periodic Health Examination Completion
Description: all available players completed a mandatory PHE on one of three days during the first week of the season. Typically, the musculoskeletal and performance components of the PHE included: 1) anthropometric measurements; 2) medical history (i.e. previous injury history); 3) musculoskeletal examination tests; 4) functional movement and balance tests; 5) strength and power tests.
Study: NCT00981266

Intervention type: DEVICE
Group type: OTHER
Intervention: Mentor Spectra/Becker 80 Breast Implant
Description: The Mentor Smooth Spectra/Becker 80 Adjustable Breast Implant has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over a period of time via the fill tube by injecting saline through the injection dome. Once filled to the desired volume, the fill tube and injection dome are removed, and the prosthesis remains in position as a breast implant. Its purpose is to provide volume flexibility and projection adjustability.

Intervention type: DEVICE
Group type: OTHER
Intervention: Mentor Spectra/Becker 80 Breast Implant
Description: The Mentor Smooth Spectra/Becker 80 Adjustable Breast Implant has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over a period of time via the fill tube by injecting saline through the injection dome. Once filled to the desired volume, the fill tube and injection dome are removed, and the prosthesis remains in position as a breast implant. Its purpose is to provide volume flexibility and projection adjustability.
Study: NCT04322799

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Device: Randomization between prosthetic components
Description: Patients are randomized between two types of cup components in total hip arthroplasty. Identical cups made of either highly-crosslinked polyethylene or conventional polyethylene.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Device: Randomization between prosthetic components
Description: Patients are randomized between two types of cup components in total hip arthroplasty. Identical cups made of either highly-crosslinked polyethylene or conventional polyethylene.
Study: NCT04034225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNS-301
Description: Day 0, Week 3, Week 6, Week 9 then every 6 weeks (±3 days) for 6 additional doses, thereafter every 12 weeks (±3 days) up to 24 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (200 mg dose) IV infusion will be administered over 30 minutes every 3 weeks up to 24 months or Pembrolizumab (400 mg dose) IV will be administered over 30 minutes every 6 weeks up to 24 months.
Study: NCT02240901

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway（LMA）
Description: Laryngeal mask airway（LMA） is used to maintain mechanical ventilation during intra-operative

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation（ETI）
Description: Endotracheal intubation group（ETI）is used to maintain mechanical ventilation during intra-operative
Study: NCT01071902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidex otic solution
Description: 4 drops into the infected ear(s) twice daily (morning and evening) for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin otic solution
Description: 4 drops into the infected ear(s) twice daily (morning and evening) for 7 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: 4 drops into the infected ear(s) twice daily (morning and evening) for 7 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tympanostomy tubes
Description: Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tympanostomy tubes
Description: Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Tympanostomy tubes
Description: Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
Study: NCT01111331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 25 mg
Description: 25 mg BI 10773 qd for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin 25 mg
Description: 25 mg Warfarin single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 25 mg
Description: 25 mg BI 10773 qd for 12 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: 25 mg warfarin single dose with and without 50 mg BI 10773
Study: NCT03428490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fully integrated treatment
Description: Clinicians will be delivering CBT for Social Anxiety Disorder directly into the context of the Matrix's evidence-based treatment for substance use disorders (i.e., The Matrix Model).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stand-alone Intensive Outpatient Program
Description: Evidence-based treatment for substance use disorders (i.e., The Matrix Model).
Study: NCT04065412

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laryngeal handshake technique
Description: The conventional laryngeal handshake technique is performed with the non-dominant hand, identifying the hyoid bone and thyroid laminae, stabilizing the larynx between thumb and middle finger, and moving down the neck to palpate the cricothyroid membrane with the index finger.
Study: NCT04457609

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azithromycin
Description: Current standardized treatment for Covid-19

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Current standardized treatment for Covid-19

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Mesenchymal Stem Cells
Description: Adjuvant therapy on top of current standardized treatment (Oseltamivir + Azithromycin)
Study: NCT03576664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Cross-over, randomized, placebo-controlled study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Cross-over, randomized, placebo-controlled study.
Study: NCT01491191

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide
Description: Before surgery: 600 mg cp twice a day After surgery: 600 mg microgranules twice a day for 10 days then 600 mg cps once a day for 20 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Before surgery: 1 sugar pill twice a day for 8 days After surgery: 1 sugar microgranules twice a day for 10 days then 1 sugar pill once a day for 20 days
Study: NCT02649569

Intervention type: DEVICE
Intervention: Monitoring Device
Description: Wear activity monitor

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Complete the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30
Study: NCT04634006

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home-based transcranial direct current (tDCS) device
Description: tDCS is a brain electrostimulation technique that consists of applying a current of low intensity (between 1 and 2 mA) on the scalp via two electrodes in order to modify the cerebral activity of the stimulated zones. Twenty sessions (active/sham) will be self-administered by parent or caregiver on twenty consecutive business days. The parameter of electrode size, current strength and current duration were previously tested for safety in children. The investigators use the Soterix Medical tDCS devices of the home-based miniCT 1x1 type.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home-based transcranial direct current (tDCS) device
Description: tDCS is a brain electrostimulation technique that consists of applying a current of low intensity (between 1 and 2 mA) on the scalp via two electrodes in order to modify the cerebral activity of the stimulated zones. Twenty sessions (active/sham) will be self-administered by parent or caregiver on twenty consecutive business days. The parameter of electrode size, current strength and current duration were previously tested for safety in children. The investigators use the Soterix Medical tDCS devices of the home-based miniCT 1x1 type.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Home-based transcranial direct current (tDCS) device
Description: tDCS is a brain electrostimulation technique that consists of applying a current of low intensity (between 1 and 2 mA) on the scalp via two electrodes in order to modify the cerebral activity of the stimulated zones. Twenty sessions (active/sham) will be self-administered by parent or caregiver on twenty consecutive business days. The parameter of electrode size, current strength and current duration were previously tested for safety in children. The investigators use the Soterix Medical tDCS devices of the home-based miniCT 1x1 type.
Study: NCT00828165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-300, MEK inhibitor; oral
Description: single dose, escalating

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study: NCT01088230

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Botox®
Description: the treatment group will receive a one time injection of Botox® at the wrist flexors and pronators of the affected arm. Each subject will receive a standard dose of 150 units total, 50u each to the flexor carpi radialis and flexor carpi ulnaris, and 25u each for the pronator teres and pronator quadratus muscle groups.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: the control group will receive a one time injection of salt water in the flexor carpi radialis and flexor carpi ulnaris, and the pronator teres and pronator quadratus muscle groups.
Study: NCT01439256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Controlled Telephone Counseling
Description: The subjects in the intervention arm receive medication adherence counseling through a computer controlled telephone counseling program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physician information and management recommendations
Description: Treating physicians for those subjects in the intervention arm receive through the medical record system a summary of blood pressure values and adherence data and recommendations.
Study: NCT03289819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w. After the 25th patient has started trial treatment, all further included patients will receive 1 cycle of pembrolizumab i.v. 200 mg q3w monotherapy followed by 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
Study: NCT04065412

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified laryngeal handshake technique
Description: The modified laryngeal handshake is performed with the non-dominant hand, stabilizing the trachea between thumb and middle finger from the suprasternal notch and moving up the neck to palate the cricoid cartilage and cricothyroid membrane with the index finger.
Study: NCT00816543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOCETAXEL
Description: 50 mg/m² IV as a 1 hour infusion on day 1 for each period of 3 weeks for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: 80mg/m² day 1-14 every 3 weeks for 3 cycles. The curative resection group will receive two oral doses of 40 mg/m²/day for 4 weeks, followed by 2 weeks rest, for 1 year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXALIPLATIN
Description: 100 mg/m² on day 1 as a two-hour IV infusion for each period of 3 weeks for 3 cycles.
Study: NCT00208702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triiodothyronine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sertraline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Study: NCT03221803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OT Vertical attachment
Description: new extra coronal castable attachment
Study: NCT04340167

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous humanized anti-CD22 chimeric antigen receptor T cells
Description: CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis and frozen for multiple uses. Before each CAR T-cell infusion (day 0), patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (250 mg/m2/day) on days -5 to -3. No bridging chemotherapy was given between enrollment and infusion. In CD22 T cell clinical trials, CAR-T cells was given once. All patients underwent bone marrow (BM) biopsy examination and radiology studies on days 30 and every month to determine the response and remission status. Bone biopsy, MRD status by FCM and RT-PCR (if the patient had fusion gene), and EMDs evaluation by CT/MRI/PET-CT were also conducted before CAR T-cell infusion to determine the disease status.